BAFNAPHARM Intraday Analysis...

BAFNAPHARM Share Price

Open 26.80 Change Price %
High 26.95 1 Day -2.25 -8.30
Low 24.60 1 Week -2.85 -10.29
Close 24.85 1 Month -5.00 -16.75
Volume 47641 1 Year -4.55 -15.48
52 Week High 35.95
52 Week Low 24.60
BAFNAPHARM Important Levels
Resistance 2 27.03
Resistance 1 26.13
Pivot 25.47
Support 1 23.57
Support 2 22.67
NSE INDIA Most Active Stocks
RCOM 20.50 -20.39%
JPASSOCIAT 11.05 -12.65%
SINTEX 28.95 -4.14%
SUNPHARMA 502.60 -11.46%
SUZLON 19.15 -3.28%
SOUTHBANK 26.90 -0.37%
ADANIPOWER 26.70 -7.61%
GMRINFRA 14.80 -7.21%
ITC 315.85 2.18%
ITC 315.85 2.18%
More..
NSE INDIA Top Gainers Stocks
KSERASERA 0.15 50.00%
RASOYPR 0.20 33.33%
FCSSOFT 0.25 25.00%
SOTL 1178.20 20.00%
PGIL 135.75 19.97%
HILTON 27.35 19.96%
PCJEWELLER 512.90 13.76%
ALANKIT 26.45 12.55%
MAANALU 148.65 9.99%
KESARENT 134.05 9.97%
More..
NSE INDIA Top Losers Stocks
RCOM 20.50 -20.39%
LCCINFOTEC 0.20 -20.00%
CGPOWER 78.90 -15.48%
MIC 9.95 -15.32%
MIC 9.95 -15.32%
MIC 9.95 -15.32%
MIC 9.95 -15.32%
AKSHARCHEM 790.55 -12.89%
JPASSOCIAT 11.05 -12.65%
REIAGROLTD 0.35 -12.50%
More..

Bafna Pharmaceuticals Limited (NSE: BAFNAPHARM)

BAFNAPHARM Technical Analysis 5
As on 29th May 2017 BAFNAPHARM Share Price closed @ 24.85 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 30.15 & Strong Sell for SHORT-TERM with Stoploss of 29.63 we also expect STOCK to react on Following IMPORTANT LEVELS.
BAFNAPHARM Target for May
1st Target up-side 31.89
2nd Target up-side 33.33
3rd Target up-side 34.76
1st Target down-side 27.81
2nd Target down-side 26.37
3rd Target down-side 24.94
BAFNAPHARM Synopsis Technicals View
50 Day EMA N/A (Short Term)
N/A
100 Day EMA N/A (Mid Term) N/A
200 Day EMA N/A (Long Term) N/A
MACD (12 26 9) N/A N/A
RSI (14) N/A N/A
MFI (14) N/A N/A
CCI (20) N/A N/A
WILLIAM %R (14) N/A N/A
ADX (14) N/A N/A
PSAR N/A N/A
10 Day Avg Volume N/A
BAFNAPHARM Other Details
Segment EQ
Market Capital 0.00
Sector Pharmaceuticals
Industry
Offical website
BAFNAPHARM Address
BAFNAPHARM
N/A
BAFNAPHARM Latest News
BCCL to invest around $3.2M in Lifezen Healthcare   VC Circle   - 19th Mar 15
Bafna Pharmaceuticals clears renewal audit by MHRA-UK   Equity Bulls   - 04th Mar 15
Bafna Pharma stock rallies 8%   Indiainfoline   - 02nd Mar 15
Strides Arcolab acquires majority stake in Bafna Pharma   Daily News & Analysis   - 22nd Jul 14
Bafna Pharmaceuticals Limited   Moneycontrol.com   - 26th Nov 13
Bafna Pharmaceuticals recommends 6% dividend for 2012-13   Economic Times   - 22nd May 13
Bafna Pharma's Raricap sales double in FY13   Myiris.com   - 10th May 13
Bafna Pharma Obtains Ghana FDA Nod To Market Omeran Capsules   RTT News   - 03rd May 13
Bafna Pharma to focus on haematinic drug mkt   Business Standard (blog)   - 13th Apr 11
Bafna Pharma: Stock provides little incentives   Economic Times   - 04th Apr 11
Interactive Technical Analysis Chart Bafna Pharmaceuticals Limited ( BAFNAPHARM NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Bafna Pharmaceuticals Limited
BAFNAPHARM Business Profile
Bafna was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and has been engaged in the business of manufacturing pharmaceutical formulations of Betalactum and Non Betalactum products. The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a. During the year 1995, Bafna Pharmaceuticals Limited was incorporated and it acquired the entire business of the proprietary concern. During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products. During 2006, Bafna has set up a 100% EOU unit at Madhavaram for the production of tablets and capsule with a capacity of 6973.20 lacs and 2462.40 lacs. This facility has been set up as per revised Schedule M under the Drugs and Cosmetics Act, 1947. The manufactured products in this factory catered to the markets of Srilanka, Ghana and Ukraine. Bafna was carrying on contract manufacturing for M/s Croslands Pvt. Ltd, a Mumbai based Pharmaceutical Company during the period 1994 to 2000. The current market capitalization stands at Rs 49.07 crore. The company has reported a standalone sales of Rs 46.99 crore and a Net Profit of Rs 1.19 crore for the quarter ended September 2013. The company management includes Bafna Mahaveer Chand - Chairman & Managing Director, Paras Bafna - Whole Time Director, Sunil Bafna - Ind. Non-Executive Director, V Rajamani - Ind. Non-Executive Director, R Dwarakanathan - Ind. Non-Executive Director, Kamlesh Kumar - Ind. Non-Executive Director. The Registered office is at Bafna Towers, New No.68, Old No. 299, Thambu Chetty Street, Chennai (Madras), Tamil Nadu - 600001.